TCON TRACON Pharmaceuticals Inc.

3.87
-0.32  -8%
Previous Close 4.19
Open 4
Price To Book 3
Market Cap 15,867,000
Shares 4,100,000
Volume 313,394
Short Ratio
Av. Daily Volume 580,581
Stock charts supplied by TradingView

NewsSee all news

  1. TRACON Pharmaceuticals, 3D Medicines and Jiangsu Alphamab Announce Partnership for Development of Subcutaneous PD-L1 Single-Domain Antibody in Soft Tissue Sarcoma

    Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT Envafolimab represents a potential best-in-class PD-L1 inhibitor that is injectable subcutaneously without the need for an adjuvant

  2. TRACON Pharmaceuticals Announces Reverse Stock Split

    SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer

  3. TRACON Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer

  4. TRACON to Report Third Quarter 2019 Company Highlights and Financial Results on November 5, 2019

    SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer

  5. TRACON Pharmaceuticals Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

    SAN DIEGO, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Enrolment to be terminated - April 12, 2019.
TRC105 + Opdivo
Non-small cell lung cancer (NSCLC)
Phase 1/2 data due 1H 2020.
TRC253
Prostate cancer
Phase 2 data due 1H 2020.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 data December 21, 2018 did not meet primary endpoint.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 primary endpoint not met - November 19, 2018.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2020.
TRC102
Mesothelioma cancer
Phase 3 interim analysis April 12, 2019 noted trial to be terminated due to futility.
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 2 poster presented April 3, 2019 at AACR.
TRC102 and Temodar (temozolomide)
Colorectal cancer
Phase 1 data due 2H 2020.
TJ004309
Solid tumors
Pivotal trial plans to be discussed with the FDA in early 2020.
Envafolimab
Sarcomas

Latest News

  1. TRACON Pharmaceuticals, 3D Medicines and Jiangsu Alphamab Announce Partnership for Development of Subcutaneous PD-L1 Single-Domain Antibody in Soft Tissue Sarcoma

    Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT Envafolimab represents a potential best-in-class PD-L1 inhibitor that is injectable subcutaneously without the need for an adjuvant

  2. TRACON Pharmaceuticals Announces Reverse Stock Split

    SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer

  3. TRACON Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer

  4. TRACON to Report Third Quarter 2019 Company Highlights and Financial Results on November 5, 2019

    SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer

  5. TRACON Pharmaceuticals Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

    SAN DIEGO, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer,

  6. TRACON Pharmaceuticals Announces that Scientific Advisor William Kaelin, Jr., M.D. was Awarded the 2019 Nobel Prize in Physiology or Medicine

    SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), announced today that William Kaelin Jr., M.D., a member of TRACON's Scientific Advisory Board since 2011, and Professor of Medicine at

  7. TRACON Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference Sponsored by H.C. Wainwright

    SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer,

  8. TRACON Pharmaceuticals to Present at the 2019 Wells Fargo Securities Healthcare Conference

    SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer,

  9. TRACON Pharmaceuticals to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith

    SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer,